Citation
D'Souza, Deepak Cyril, et al. "The Psychotomimetic Effects of Intravenous Delta-9-tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis." Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, vol. 29, no. 8, 2004, pp. 1558-72.
D'Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29(8):1558-72.
D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y. T., Braley, G., Gueorguieva, R., & Krystal, J. H. (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, 29(8), 1558-72.
D'Souza DC, et al. The Psychotomimetic Effects of Intravenous Delta-9-tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis. Neuropsychopharmacology. 2004;29(8):1558-72. PubMed PMID: 15173844.
TY - JOUR
T1 - The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis.
AU - D'Souza,Deepak Cyril,
AU - Perry,Edward,
AU - MacDougall,Lisa,
AU - Ammerman,Yola,
AU - Cooper,Thomas,
AU - Wu,Yu-Te,
AU - Braley,Gabriel,
AU - Gueorguieva,Ralitza,
AU - Krystal,John Harrison,
PY - 2004/6/3/pubmed
PY - 2004/9/9/medline
PY - 2004/6/3/entrez
SP - 1558
EP - 72
JF - Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
JO - Neuropsychopharmacology
VL - 29
IS - 8
N2 - Recent advances in the understanding of brain cannabinoid receptor function have renewed interest in the association between cannabinoid compounds and psychosis. In a 3-day, double-blind, randomized, and counterbalanced study, the behavioral, cognitive, and endocrine effects of 0, 2.5, and 5 mg intravenous delta-9-tetrahydrocannabinol (Delta-9-THC) were characterized in 22 healthy individuals, who had been exposed to cannabis but had never been diagnosed with a cannabis abuse disorder. Prospective safety data at 1, 3, and 6 months poststudy was also collected. Delta-9-THC (1) produced schizophrenia-like positive and negative symptoms; (2) altered perception; (3) increased anxiety; (4) produced euphoria; (5) disrupted immediate and delayed word recall, sparing recognition recall; (6) impaired performance on tests of distractibility, verbal fluency, and working memory (7) did not impair orientation; (8) increased plasma cortisol. These data indicate that Delta-9-THC produces a broad range of transient symptoms, behaviors, and cognitive deficits in healthy individuals that resemble some aspects of endogenous psychoses. These data warrant further study of whether brain cannabinoid receptor function contributes to the pathophysiology of psychotic disorders.
SN - 0893-133X
UR - https://www.unboundmedicine.com/medline/citation/15173844/The_psychotomimetic_effects_of_intravenous_delta_9_tetrahydrocannabinol_in_healthy_individuals:_implications_for_psychosis_
L2 - https://facultyopinions.com/pubmed/15173844
DB - PRIME
DP - Unbound Medicine
ER -